Literature DB >> 3024646

A possible role for membrane lipid peroxidation in anthracycline nephrotoxicity.

E G Mimnaugh, M A Trush, T E Gram.   

Abstract

Adriamycin causes both glomerular and tubular lesions in kidney, which can be severe enough to progress to irreversible renal failure. This drug-caused nephrotoxicity may result from the metabolic reductive activation of Adriamycin to a semiquinone free radical intermediate by oxidoreductive enzymes such as NADPH-cytochrome P-450 reductase and NADH-dehydrogenase. The drug semiquinone, in turn, autoxidizes and efficiently generates highly reactive and toxic oxyradicals. We report here that the reductive activation of Adriamycin markedly enhanced both NADPH- and NADH-dependent kidney microsomal membrane lipid peroxidation, measured as malonaldehyde by the thiobarbituric acid method. Adriamycin-enhanced kidney microsomal lipid peroxidation was diminished by the inclusion of the oxyradical scavengers, superoxide dismutase and 1,3-dimethylurea, and by the chelating agents, EDTA and diethylenetriamine-pentaacetic acid (DETPAC), implicating an obligatory role for reactive oxygen species and metal ions in the peroxidation mechanism. Furthermore, the inclusion of exogenous ferric and ferrous iron salts more than doubled Adriamycin-stimulated peroxidation. Lipid peroxidation was prevented by the sulfhydryl-reacting agent, p-chloromercuribenzenesulfonic acid, by omitting NAD(P)H, or by heat-inactivating the kidney microsomes, indicating the requirement for active pyridine-nucleotide linked enzymes. Several analogs of Adriamycin as well as mitomycin C, drugs which are capable of oxidation-reduction cycling, greatly increased NADPH-dependent kidney microsomal peroxidation. Carminomycin and 4-demethoxydaunorubicin were noteworthy in this respect because they were three to four times as potent as Adriamycin. In isolated kidney mitochondria, Adriamycin promoted a 12-fold increase in NADH-supported (NADH-dehydrogenase-dependent) peroxidation. These observations clearly indicate that anthracyclines enhance oxyradical-mediated membrane lipid peroxidation in vitro, and suggest that peroxidation-caused damage to kidney endoplasmic reticulum and mitochondrial membranes in vivo could contribute to the development of anthracycline-caused nephrotoxicity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3024646     DOI: 10.1016/0006-2952(86)90713-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  11 in total

1.  Remedial effect of DL-alpha-lipoic acid against adriamycin induced testicular lipid peroxidation.

Authors:  Chidambaram Prahalathan; Elangovan Selvakumar; Palaninathan Varalakshmi
Journal:  Mol Cell Biochem       Date:  2004-12       Impact factor: 3.396

Review 2.  Clinical pharmacokinetics of doxorubicin.

Authors:  P A Speth; Q G van Hoesel; C Haanen
Journal:  Clin Pharmacokinet       Date:  1988-07       Impact factor: 6.447

3.  Curcumin prevents adriamycin nephrotoxicity in rats.

Authors:  N Venkatesan; D Punithavathi; V Arumugam
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

4.  The influence of lipoic acid on adriamycin induced nephrotoxicity in rats.

Authors:  Kumaravel Palanichamy Malarkodi; Andithangal Venkatesan Balachandar; Palaninathan Varalakshmi
Journal:  Mol Cell Biochem       Date:  2003-05       Impact factor: 3.396

5.  Protective effect of lipoic acid on adriamycin induced lipid peroxidation in rat kidney.

Authors:  Kumaravel Palanichamy Malarkodi; Andithangal Venkatesan Balachandar; Palaninathan Varalakshmi
Journal:  Mol Cell Biochem       Date:  2003-05       Impact factor: 3.396

6.  The effect of chronic adriamycin treatment on heart kidney and liver tissue of male and female rat.

Authors:  R H Julicher; L Sterrenberg; G R Haenen; A Bast; J Noordhoek
Journal:  Arch Toxicol       Date:  1988       Impact factor: 5.153

7.  Increased renal susceptibility to gentamicin in the rat with obstructive jaundice. Role of lipid peroxidation.

Authors:  K Tajiri; H Miyakawa; F Marumo; C Sato
Journal:  Dig Dis Sci       Date:  1995-05       Impact factor: 3.199

8.  Fibronectin expression in human mesangial cell cultures and its alterations by adriamycin.

Authors:  M Soose; S Wenzel; A Padur; D Oberst; H Stolte
Journal:  Cell Biol Toxicol       Date:  1995-02       Impact factor: 6.691

9.  Fibronectin turnover in human mesangial cell cultures as affected by adriamycin.

Authors:  M Soose; S Wenzel; H Stolte
Journal:  Cell Biol Toxicol       Date:  1993 Apr-Jun       Impact factor: 6.691

10.  The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice.

Authors:  Majid Ali; Marzieh Kamjoo; Huw D Thomas; Suzanne Kyle; Ivanda Pavlovska; Muhammed Babur; Brian A Telfer; Nicola J Curtin; Kaye J Williams
Journal:  Mol Cancer Ther       Date:  2011-09-16       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.